Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Vanina Popova, M.D., Ella J. Daly, M.D., Madhukar Trivedi, M.D., Kimberly Cooper, M.S., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Mazzucco, M.Sc., David Hough, M.D., Michael E. Thase, M.D., Richard C. Shelton, M.D., Patricio Molero, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Malek Bajbouj, M.D., Husseini Manji, M.D., Wayne C. Drevets, M.D., Jaskaran B. Singh, M.D. American Journal of Psychiatry in Advance, 2019 ajp.psychiatryonline.org doi: 10.1176/appi.ajp.2019.19020172 Objective : About one-third of patients with depression fail to achieve remission despite treatment with multiple [...]
Lire la suiteLe Cannabidiol, l’autre canabinoïde présent dans le cannabis : une piste thérapeutique prometteuse? Traiter la dépendance avec du cannabidiol ? Si peu d’études ont pour l’heure été menées chez l’Homme, l’idée fait son chemin... et inspire les instigateurs d’une étude-pilote «CANNAVAP». Grégoire Cleirec et Pierre Poloméni Publié le 20 Mai 2019 par : Revue SWAPS n°90, "Du Cannabis Thérapeutique à la Régulation". http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891 L’Agence nationale de sécurité du médicament (ANSM) a annoncé récemment la création d’un comité scientifique spécialisé sur «l’évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France». Une façon de combler notre retard. À [...]
Lire la suiteRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C. Andrade, Morgana M. Novaes, Jessica A. Pessoa, Sergio A. Mota-Rolim, Flávia L. Osório, Rafael Sanches, Rafael G. dos Santos, Luís Fernando Tófoli, Gabriela de Oliveira Silveira, Mauricio Yonamine7, Jordi Riba, Francisco R. Santos, Antonio A. Silva-Junior, João C. Alchieri10, Nicole L. Galvão-Coelho5,11, Bruno Lobão-Soares5,12, Jaime E. C. Hallak, Emerson Arcoverde, João P. Maia-de-Oliveira and Dráulio B. Araújo Psychological Medicine, June 2018, 1-9 https://www.cambridge.org/core doi.org/10.1017/S0033291718001356 Abstract Background. Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods. [...]
Lire la suiteThe alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Jose A. Morales-García, Mario de la Fuente Revenga, Sandra Alonso-Gil, María Isabel Rodríguez-Franco, Amanda Feilding, Ana Perez-Castillo & Jordi Riba Scientific Reports, 2017, 7, 5309 www.nature.com/scientificreports https://www.nature.com/articles/s41598-017-05407-9 DOI:10.1038/s41598-017-05407-9 Abstract : Banisteriopsis caapi is the basic ingredient of ayahuasca, a psychotropic plant tea used in the Amazon for ritual and medicinal purposes, and by interested individuals worldwide. Animal studies and recent clinical research suggests that B. caapi preparations show antidepressant activity, a therapeutic effect that has been linked to hippocampal neurogenesis. Here we report that harmine, tetrahydroharmine and harmaline, the [...]
Lire la suite